NEWS
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
Tonix Pharmaceuticals (NASDAQ:TNXP) is developing TNX-801, a vaccine candidate to combat the escalating mpox global health crisis. The vaccine is based on Edward Jenner's smallpox vaccine technology from the 1700s, which successfully eradicated smallpox. TNX-801 has shown promise in non-human primate studies, protecting against lethal doses of the Clade 1 monkeypox virus.
Tonix Pharmaceuticals (NASDAQ:TNXP) is developing TNX-801, a vaccine candidate to combat the escalating mpox global health crisis. The vaccine is based on Edward Jenner's smallpox vaccine technology from the 1700s, which successfully eradicated smallpox. TNX-801 has shown promise in non-human primate studies, protecting against lethal doses of the Clade 1 monkeypox virus.
Key features of TNX-801 include:
Single-dose administration
Potential for long-term immunity
Ability to prevent forward transmission
No need for complex cold-chain storage
The vaccine platform has also been selected for the NIH's NextGen program for COVID-19 vaccine development.
Tonix's technology recently received a $34 million contract from the U.S. Department of Defense for developing a broad-spectrum antiviral against potential biowarfare agents
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow
Lnova :
bought